By: Christine Drury From: iu.edu Five years ago, Jackie Stephens rolled over in bed and felt a horrible pain in her right breast. A subsequent mammogram revealed a large lump in her right breast and two smaller ones. Her diagnosis: triple negative breast cancer. Stephens’ oncologist prescribed a treatment regimen of chemotherapy, a lumpectomy and radiation. When her treatment was …
Harbor Branch Oceanographic Institute researches ‘promising’ triple-negative breast cancer treatment
By: Meghan McRoberts From: wptv.com Researchers at FAU’s Harbor Branch Oceanographic Institute have been awarded a large grant to look into the chance that a chemical released by sea sponges in various oceans could treat an aggressive form of breast cancer. “I find it really, really promising,” said Associate Research Professor, Dr. Esther Guzman. She is leading the research project …
Let Life Happen Teams With Breast Advocate®
View PostBiovica Publishes a Summary of Study-results in Breast Cancer With DiviTum®
This information was brought to you by Cision http://news.cision.com From: biospace.com Biovica has a comprehensive study program with DiviTum® to demonstrate the clinical value for cancer patients. Biovica has published a summary brochure in order to share knowledge about results achieved so far with DiviTum® to researchers, oncologists and other stakeholders. The summary describes all clinical studies presented where DiviTum® …
FDA Approves Qiagen’s PIK3CA Test as Companion Test for Novartis Breast Cancer Drug
By: Staff Reporter From: genomeweb.com The US Food and Drug Administration has approved Qiagen’s Therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for identifying which advanced breast cancer patients have PIK3CA mutations and are likely to respond to Novartis’ alpelisib (Piqray). The test is designed to analyze PIK3CA mutations in tissue and blood samples. Patients who are mutation negative …
Investigators Slow Growth by Starving Triple-Negative Breast Cancer Cells
By: Jennifer Nesse From: specialtypharmacytimes.com Investigators from the Brazilian Biosciences National Laboratory have developed a strategy for slowing the growth of triple-negative breast cancer (TNBC) that involves cutting cancerous cells off from vital food sources. The study, published in the Journal of Biological Chemistry, focused on TNBC tumors, which often lack estrogen progesterone receptors and human epidermal growth factor receptor …
Research provides insight into genetic link to potential treatment response among BRCA1/2 breast cancer patients
By: Alex Gardner From: medicalxpress.com New findings from researchers in the Perelman School of Medicine at the University of Pennsylvania provide clues about immune response of tumors in patients with BRCA 1/2-related breast cancers. The research, published in the journal Clinical Cancer Research, could shape treatment strategies and clinical trial design for these patients, who make up about two percent …
Metastatic Breast Cancer Genomes Point to Distinct Features, Tumor Evolution
By: Staff Reporter From: genomeweb.com A team from France, Switzerland, and the US has characterized genomic alterations that are specific to advanced, metastatic forms of breast cancer using exome sequence and clinical outcome data. As they reported online today in Nature, the researchers did whole-exome sequencing on samples from more than 600 individuals with metastatic breast cancer, identifying alterations that …
MIT CSAIL’s AI can predict the onset of breast cancer 5 years in advance
By: Kyle Wiggers From: venturebeat.com Breast cancer is the second leading cancer-related cause of death among women in the U.S. It’s estimated that in 2015, 232,000 women were diagnosed with the disease and approximately 40,000 died from it. And while exams like mammography have come into wide practice — in 2014, over 39 million breast cancer screenings were performed in …
Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
Source: Business Wire From: yahoo.com Positive opinion based on results from largest Phase 3 trial performed to date of a PARP inhibitor in gBRCA-mutated advanced breast cancer Pfizer Inc. (PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase …